Kidney failure patients may get new weight-loss option
NCT ID NCT07176663
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests the safety and effectiveness of tirzepatide (Spartina) for weight loss in 15 adults with chronic kidney failure who also have diabetes or a BMI over 27. The drug is already used for diabetes and weight management, but its effects in kidney failure patients need more study. Participants must not have used similar therapy for less than 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Nooshin Dalili
Tehran, 1666663421, Iran
Conditions
Explore the condition pages connected to this study.